Comparison of the efficacy between immunochemotherapy and chemotherapy in gastric cancer accompanied with synchronous liver metastases: A real-world retrospective study.

Autor: Lin GT; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China., Liu ZY; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China., Shang-Guan ZX; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China., Zeng GR; Fujian Medical University Diagnostic Pathology Center, Fujian Medical University, Fuzhou, China., Lin JX; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China., Wu J; Department of General Surgery, Affiliated Zhongshan Hospital of Dalian University, Dalian, China., Chen QY; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China., Xie JW; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China., Li P; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China., Huang CM; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China., Zheng CH; Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, China.; Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China.
Jazyk: angličtina
Zdroj: Cancer medicine [Cancer Med] 2023 Jun; Vol. 12 (11), pp. 12221-12233. Date of Electronic Publication: 2023 Apr 16.
DOI: 10.1002/cam4.5917
Abstrakt: Background: Few studies have investigated the efficacy of comprehensive therapies, including immunotherapy, for gastric cancer with synchronous liver metastases (GCLM). We retrospectively compared the effect of immunochemotherapy and chemotherapy alone as conversion therapies on the oncological outcomes of patients with GCLM.
Methods: The clinicopathological data of 100 patients with GCLM from February 2017 to October 2021 at our institution were retrospectively analyzed. Patients were divided into immunochemotherapy (n = 33) and chemotherapy-alone (n = 67) groups.
Results: Baseline clinicopathological data did not differ significantly between the two groups. The immunochemotherapy group had a higher overall response rate (59.4% vs. 44.0%, p = 0.029) and disease control rate (71.9% vs. 49.2%, p = 0.036) than the chemotherapy group. The immunochemotherapy group showed better tumor regression in the gastric mass, metastatic lymph nodes, and liver lesions than the chemotherapy group. Ten (30.3%) patients in the immunochemotherapy group and 13 (19.4%) patients in the chemotherapy group underwent surgery after conversion therapy. However, the difference was not statistically significant. The overall survival (OS) and progression-free survival (PFS) rates were better in the immunochemotherapy group than in the chemotherapy group. Treatment-related adverse events occurred in 24 (72.7%) and 47 (70.1%) patients in the immunochemotherapy and chemotherapy groups, respectively.
Conclusions: As a conversion therapy for GCLM, immunotherapy yielded better primary and metastatic tumor regression and survival benefits, with no increase in adverse events compared to chemotherapy.
(© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje